Holen Sie sich die Stockscreener-App
31.11
4.78%
-1.56
Vorhandelsmarkt:
32.17
1.06
+3.41%
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Immunovant Inc stock (US45258Q1058): shares trade around mid-30 USD ahead of next catalysts - AD HOC NEWS
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary - Yahoo Finance
Behavioral Patterns of IMVT and Institutional Flows - Stock Traders Daily
IMVT Technical Analysis & Stock Price Forecast - Intellectia AI
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data - Insider Monkey
13 Best Short Squeeze Stocks to Invest In - Insider Monkey
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 - Moomoo
IMVT rockets 35% despite wider loss as arthritis drug shines in study - MSN
Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock - Moomoo
Immunovant (IMVT) director Fromkin sells 221,951 shares after exercising options - Stock Titan
Assessing Immunovant (IMVT) Valuation After Strong Recent Share Price Momentum - simplywall.st
[144] Immunovant, Inc. SEC Filing - Stock Titan
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating - Insider Monkey
J.P. Morgan Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $47 - Moomoo
Selling US$2.3m Of Stock Was Lucrative Decision For Immunovant Insiders - 富途牛牛
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Nvidia, Astera Labs, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More Movers - Barron's
Stifel Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $49 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT) - Seeking Alpha
(IMVT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Immunovant (IMVT) Is Up 24.2% After Axing Batoclimab To Back IMVT-1402 Autoimmune PivotHas The Bull Case Changed? - simplywall.st
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Immunovant COO Gloria Melanie sells $101,072 in company stock By Investing.com - Investing.com Australia
Immunovant COO Gloria Melanie sells $101,072 in company stock - Investing.com
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT) - The Globe and Mail
These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Sahm
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $43 - Moomoo
Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications - TipRanks
Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider LossesHas The Bull Case Changed? - Yahoo Finance
Immunovant director Atul Pande sells $192,000 in shares By Investing.com - Investing.com Nigeria
IMVT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IMVT Maintains Buy Rating by B of A Securities -- Price Target R - GuruFocus
IMVT Maintains by HC Wainwright & Co. -- Price Target Raised to $40 - GuruFocus
Immunovant (IMVT) Stock Shot up after a Poor Quarterly Showing - FXLeaders
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV) - Seeking Alpha
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $45 - Moomoo
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data - The Globe and Mail
BofA raises Immunovant stock price target on higher peak sales outlook - Investing.com
Stifel reiterates Immunovant stock rating on trial results By Investing.com - Investing.com Australia
Immunovant director Atul Pande sells $192,000 in shares - Investing.com India
1.13%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):